Cargando…

2435: Accuracies of using Her2 for prognosis of breast cancer recurrence in Life After Cancer Epidemiology (LACE) Study

OBJECTIVES/SPECIFIC AIMS: The goal of the study is to evaluate the prognostic importance and accuracies of a biomarker, human epidermal receptor 2 (Her2), for breast cancer recurrence in a cohort study, namely Lifetime after Cancer Epidemiology (LACE). We specifically interested in the role that Her...

Descripción completa

Detalles Bibliográficos
Autor principal:	Nan Hu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2018
Materias:	Clinical Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798905/ http://dx.doi.org/10.1017/cts.2017.106

Ejemplares similares

2435. Stewardship – It’s Not Just Antibiotics and Testing
por: Sampson, Mindy, et al.
Publicado: (2023)

Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
por: Alanko, Johanna, et al.
Publicado: (2021)

Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer
por: Yardley, Denise A., et al.
Publicado: (2014)

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
por: Yardley, D A, et al.
Publicado: (2014)

Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis
por: Law, Jeanna Wallenta, et al.
Publicado: (2022)

Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC
por: Colomer, R., et al.
Publicado: (2017)

Breast cancer prognosis in relation to family history of breast and ovarian cancer
por: Thalib, L, et al.
Publicado: (2004)

Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population
por: Chen, Ruixian, et al.
Publicado: (2022)

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study
por: Kaufman, Peter A., et al.
Publicado: (2012)

Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer
por: Dackus, Gwen M. H. E., et al.
Publicado: (2020)

2027: Racial differences in leukemia prognosis: New epidemiologic analysis
por: Ma, Shuangge, et al.
Publicado: (2018)

A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study
por: Kubo, Makoto, et al.
Publicado: (2019)

Circulating lipids and breast cancer prognosis in the Malmö diet and cancer study
por: Harborg, Sixten, et al.
Publicado: (2021)

Tight-Lacing, Cycling, and Nephroptosis
Publicado: (1901)

Treatment of HR+/HER2− breast cancer in urban mainland China: results from the CancerMPact Survey 2019
por: Murali, Bhavna, et al.
Publicado: (2022)

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2013)

Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis
por: Honkanen, Tiia J., et al.
Publicado: (2021)

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
por: Groen, Emma J., et al.
Publicado: (2021)

Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
por: Kaplan, Henry G., et al.
Publicado: (2022)

A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer
por: Brezden-Masley, Christine, et al.
Publicado: (2020)

Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry
por: Ibragimova, Khava I. E., et al.
Publicado: (2021)

2435. The Impact of Treatment Strategy and Toxin Status on Outcomes of Patients with Clostridioides difficile Infections
por: Friedman, Daniel, et al.
Publicado: (2019)

2451: Optimal study design for Diagnostic Accuracy Studies: Differential verification Versus partial verification
por: Xu, Yizhe, et al.
Publicado: (2018)

Cohort profile – the Renal cell cancer: Lifestyle, prognosis and quality of life (ReLife) study in the Netherlands
por: Maurits, Jake S F, et al.
Publicado: (2023)

Pre-existing diabetes and breast cancer prognosis among elderly women
por: Luo, J, et al.
Publicado: (2015)

Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in Denmark
por: Collin, Lindsay J, et al.
Publicado: (2018)

Patterns and predictors of first and subsequent recurrence in women with early breast cancer
por: Geurts, Y. M., et al.
Publicado: (2017)

Tight Lacing
Publicado: (1871)

Tight Lacing
Publicado: (1882)

Epidemiologic and molecular risk factors for contralateral breast cancer among young women
por: Li, C I, et al.
Publicado: (2003)

Obesity and poor breast cancer prognosis: an illusion because of hormone replacement therapy?
por: Rosenberg, L, et al.
Publicado: (2009)

Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models
por: Laas, E, et al.
Publicado: (2015)

Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry
por: Ibragimova, Khava I. E., et al.
Publicado: (2023)

Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality
por: Makubate, B, et al.
Publicado: (2013)

Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time
por: Melvin, Jennifer C, et al.
Publicado: (2016)

Caveolin-1 genotypes as predictor for locoregional recurrence and contralateral disease in breast cancer
por: Godina, Christopher, et al.
Publicado: (2023)

Impact of breast cancer risk factors on clinically relevant prognostic biomarkers for primary breast cancer
por: Abubakar, Mustapha, et al.
Publicado: (2021)

Role of hormonal risk factors in HER2-positive breast carcinomas
por: Balsari, A, et al.
Publicado: (2003)

The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis
por: Engels, Charla C., et al.
Publicado: (2016)

Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
por: Bouwer, N. I., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_spl8lr19tbjvj1md0jea961aj0